Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer.

Carlotta Giani,Laura Valerio,Alberto Bongiovanni,Cosimo Durante,Giorgio Grani,Toni Ibrahim,Stefano Mariotti,Michela Massa,Fabiana Pani,Gabriella Pellegriti,Tommaso Porcelli,Domenico Salvatore,Martina Tavarelli,Massimo Torlontano,Laura D. Locati,Eleonora Molinaro,Rossella Elisei

Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer.

2020

Carlotta Giani
Laura Valerio
Alberto Bongiovanni
Cosimo Durante
Giorgio Grani
Toni Ibrahim
Stefano Mariotti
Michela Massa
Fabiana Pani
Gabriella Pellegriti
Tommaso Porcelli
Domenico Salvatore
Martina Tavarelli
Massimo Torlontano
Laura D. Locati
Eleonora Molinaro
Rossella Elisei

Background: Lenvatinib, a multikinase inhibitor, is for progressive radioiodine-refractory-differentiated thyroid cancer (RR-DTC) patients. However, there are a lot of drug-related adverse events (...

Keywords:

Internal medicine
Lenvatinib
Adverse effect
Quality of life
Thyroid cancer
multikinase inhibitor
Oncology
Expanded access
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations